Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Vanderbilt, Janssen Target Schizophrenia
by Rick Mullin
December 12, 2011
| A version of this story appeared in
Volume 89, Issue 50
Schizophrenia drug candidates generated from a two-year-old collaboration between the Vanderbilt Center for Neuroscience Drug Discovery and Janssen Pharmaceuticals will soon be ready for Phase I clinical trials. The candidates use allosteric modulators to adjust the activity of neurotransmitter receptors in the brain. “These drug candidates could lead to a fundamentally new approach to treating schizophrenia,” says P. Jeffrey Conn, codirector of the Vanderbilt center, which has been among the most aggressive academic institutes pursuing partnerships with drug companies.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter